Pharmacy Practice in Focus: Oncology
Pharmacists play a crucial role in evaluating 505(b)(2) drugs—from ensuring oncology therapeutic equivalence to improving access and outcomes.
The regulatory landscape for oncology medications continues to evolve rapidly, and the FDA’s 505(b)(2) pathway has emerged as an important route for bringing innovative, reformulated, or otherwise differentiated products to market more efficiently. For pharmacists, understanding how 505(b)(2) products are developed, evaluated, and integrated into patient care is essential. These medications can offer clinical and operational benefits, but they also introduce unique considerations. By examining the pharmacist’s clinical, operational, and financial responsibilities, we can better appreciate the comprehensive role pharmacists play in ensuring appropriate use of 505(b)(2) products.
The 505(b)(2) approval pathway allows manufacturers to rely on existing data from a reference listed drug (RLD), reducing the need for extensive new clinical trials while still meeting rigorous FDA requirements. This approach can accelerate time to market and decrease development cost.1,2 Importantly, 505(b)(2) products must still demonstrate therapeutic equivalence through bioavailability, bioequivalence studies, or focused clinical trials confirming they match the performance of the RLD.2,3
For pharmacists, this matters clinically because many 505(b)(2) drugs enter the market as reformulations or alternative dosage forms that may improve adherence, enhance tolerability, or simplify administration. These benefits—paired with greater accessibility— make them increasingly relevant in modern oncology practice.1,4
Pharmacists play a multifaceted clinical role that is essential for optimizing patient outcomes with these products. Clinically, core responsibilities include verifying therapeutic equivalence and confirming the 505(b)(2) product performs comparably to the original through comprehensive medication reviews that integrate chemotherapy, supportive care, and comorbidity management.5 Pharmacists can conduct detailed medication reconciliation at patient encounters, identifying drug-drug interactions, drug-disease interactions, inappropriate dosing for renal or hepatic function, and potential duplications or omissions. They provide extensive patient education and counseling on proper medication administration, expected adverse effects, adherence strategies, and when to contact the care team.6,7 Through proactive toxicity monitoring and symptom management, pharmacists can assess laboratory parameters, manage adverse drug reactions, and make dose modifications under collaborative practice agreements or relevant policies, significantly reducing adverse events and improving quality of life.
Additionally, pharmacists can facilitate financial assistance programs to address affordability barriers, coordinate prior authorizations to minimize treatment delays, and serve as accessible points of contact for patients experiencing treatment-related concerns. In community oncology specifically, embedded pharmacists document substantial clinical interventions—including anticancer drug dose adjustments, supportive care optimization, and drug interaction management—that demonstrate both improved patient safety and significant cost avoidance, with findings from studies showing a 560% return on investment while reducing adverse drug reaction rates by 62%.6-8 This integrated approach positions pharmacists as essential members of the multidisciplinary oncology team, ensuring that 505(b)(2) products and all cancer therapies are used safely, effectively, and in a patient-centered manner.
In addition to their clinical role, pharmacists also ensure safe and efficient operational integration of 505(b)(2) products within a practice. Specifically, their expertise in the execution of therapeutic interchanges and the prevention of medication-related errors is imperative for effective and safe operational success.
As previously mentioned, pharmacist-led therapeutic interchange, per practice-specific policies, has proved to be an effective process to streamline workflow and maximize drug margin.8 Some 505(b)(2) products do not have distinguishable brand names, which makes it difficult to differentiate them from their RLD in some electronic health records and on drug labels. Because of this, extra steps are often required to ensure that authorization, pharmacy, and nursing teams are aware of which products to authorize, purchase, prepare, and administer. In the absence of bar code scanning, manual editing of drug labels to indicate that a 505(b)(2) product is being used is often needed to ensure pharmacy and nursing staff are aware.
Additionally, pharmacists may have insight into which payers cover specific 505(b)(2) products. Selecting a 505(b)(2) product for payers who will reimburse for the medication can streamline efficiency and prevent rework by the authorization team. Establishing a process for clear, consistent communication with the authorization team is also imperative, as these products have unique J-codes, unlike biosimilar products. Ensuring the correct J-code is authorized is crucial for proper reimbursement post treatment.
Pharmacists also play an important role in preventing dispensing errors. 505(b)(2) products have the same active ingredient name on packaging but often require different storage, dilution instructions, infusion rates, concentrations, and administration routes from their RLDs. A systematic review of medication dispensing error trends found that up to 47.9% of errors were related to look-alike/sound-alike drugs.9 Therefore, pharmacist education for pharmacy and nursing teams on key differences between the products is an important first step to prevent medication errors. Additional drug labeling in the pharmacy helps prevent the wrong product from being selected for compounding. Attention to dilution and concentration differences is needed to verify accurate compounding. Finally, proper labeling of infusion rates and routes of administration is important to prevent administration errors once the medication leaves the pharmacy.
ABOUT THE AUTHORS
Alexa Basilio, PharmD, BCOP, is an oncology pharmacy specialist at McKesson.
Andrea Roman, PharmD, BCOP, is a senior clinical pharmacist at McKesson and US Oncology.
Julianne Darling, PharmD, BCOP, is an oncology clinical pharmacist at McKesson.
For pharmacists, particularly those involved in formulary management, procurement, and patient counseling, understanding the financial landscape surrounding these products is an essential competency. Pharmacists play a meaningful gatekeeping role when new 505(b)(2) products are being evaluated for inclusion within a practice formulary or pathways list. This role likely varies depending on the pharmacist’s practice location, whether based in a hospital/institution or community setting, but should be considered significant regardless of setting. Critical evaluation of new 505(b)(2) products is essential to ensure the potential benefit of the product outweighs the increased total cost of care.
Cost-effectiveness analysis becomes particularly important when 505(b)(2) products enter therapeutic categories where lower-cost alternatives already exist. Pharmacists should scrutinize the clinical evidence supporting the claimed advantages, because the differentiated features of a 505(b)(2) product may or may not translate to meaningful improvements for all patient populations. Similarly, although perhaps conversely, pharmacists also need to be mindful of opportunities to improve margins in drug classes that may otherwise have historically had very narrow or underwater margins. Partnering this knowledge with the understanding of payer coverage and downstream effects to the patient’s pocket is a challenge, but pharmacists are uniquely positioned to analyze these aspects of treatment.
Reimbursement dynamics further complicate financial decision-making. Many 505(b)(2) products are launched at brand-level pricing, and prior authorization requirements from payers can create workflow burden for pharmacy teams and barriers for patients. Pharmacists in ambulatory and specialty settings should be familiar with available patient assistance programs and manufacturers' co-pay support, which can partially offset out-of-pocket costs where applicable.
Finally, pharmacists play an important role in patient counseling for cancer treatment, and this counseling should include cost considerations. When patients are transitioning from an RLD to a 505(b)(2) alternative or vice versa, clear communication about any differences in expected therapeutic equivalence or cost is necessary to support patient understanding and manage expectations.
The 505(b)(2) pathway represents a rapidly expanding and consequential segment of the oncology medication landscape, offering potential opportunities for innovation, enhanced patient experience, and improved practice efficiency. Pharmacists are uniquely positioned to navigate the clinical, operational, and financial complexities across the entire life cycle of these products within a practice. From formulary evaluation and therapeutic equivalence assessment to medication reconciliation, compounding oversight, dispensing error prevention, reimbursement coordination, and patient counseling on both clinical and cost implications, the pharmacist's role is multidimensional and essential.
Critically, the financial dimensions of 505(b)(2) utilization cannot be viewed in isolation from clinical and operational considerations. Optimizing drug margins through thoughtful product selection delivers full value only when paired with accurate J-code authorization, error-free dispensing, and transparent patient communication. As the number and complexity of 505(b)(2) approvals continue to grow, pharmacists who develop expertise in evaluating these products through this integrated lens will be indispensable contributors to both the quality and sustainability of oncology care. Continued pharmacist education, standardized institutional protocols, and collaborative engagement with authorization and nursing teams will be essential to realizing the full potential of 505(b)(2) products while safeguarding patient safety and financial outcomes.
about 2 months ago
Approval Pending: How to Plan for PDUFA Decisionsabout 2 months ago
Pharmacist-Led BiTE Program at a Community Cancer Centerabout 2 months ago
Allowing Ourselves to Shrink—So We Don’t Break
